Last reviewed · How we verify
NCT02075996: Poseidon
Non-interventional Study With Pomalidomide (Imnovid®)
trial in Multiple Myeloma in 151 participants. Completed in 4 February 2021.
4 February 2021
Quick facts
| Lead sponsor | iOMEDICO AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 151 |
| Start date | 11 February 2014 |
| Primary completion | 4 February 2021 |
| Estimated completion | 4 February 2021 |
| Sites | 1 location across Germany |
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
iOMEDICO AG — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this non-interventional study is to collect data on the efficiency and safety of pomalidomide in combination with dexamethasone in the routine application
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Dechow T, Aldaoud A, Behlendorf T, Knauf W, et al · · 2022 · cited 5× · PMID 34714555 · DOI 10.1111/ejh.13719
Verify or expand the search:
- PubMed search for NCT02075996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other iOMEDICO AG trials
Trials by the same sponsor.
- NCT06619275 — Ripretinib (QINLOCK®) According to Current SmPC · completed
- NCT06181734 — Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC · completed
- NCT05954780 — Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma · active not recruiting
- NCT05517265 — Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) · active not recruiting
- NCT05284591 — Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02075996 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by iOMEDICO AG
- Last refreshed: 12 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02075996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing